Objective: To investigate the relationship between heart failure (HF) and gut microbiota-mediated energy metabolism, and to explore the role of Shenfu Injection in this process.
Materials And Methods: In this study, Adriamycin-induced chronic heart failure (CHF) rat model was used and randomly divided into the blank control group (Normal, = 9), HF control group (Model, = 12), Shenfu Injection treatment group (SFI, = 9), and positive drug control group (TMZ, = 9). The changes in gut microbiota structure were analyzed by 16S rRNA high-throughput sequencing, the content of short-chain fatty acids (SCFAs) was detected by targeted metabolomics technology, and cardiac function and energy metabolism-related indicators were evaluated.
Results: Myocardial energy metabolism in HF rats was disordered, characterized by reduced fatty acid oxidation, enhanced anaerobic glycolysis of glucose, mitochondrial damage, and decreased ATP content; The gut microbiota of HF rats was imbalanced, with a reduction in beneficial bacteria, an increase in conditional pathogenic bacteria, and impaired intestinal barrier function; Both Shenfu Injection and trimetazidine improved myocardial energy metabolism and cardiac function, but Shenfu Injection was more significant in regulating gut microbiota and improving intestinal health; The production of SCFAs from the gut microbiota of HF rats increased, which may be closely related to myocardial energy metabolism; SCFAs-producing bacteria Akkermansia and Blautia played a key role in the development of HF, and their abundance was positively correlated with SCFAs content.
Conclusion: Shenfu Injection in treating HF may improve myocardial energy metabolism and intestinal health by regulating gut microbiota, especially the abundance of SCFAs-producing bacteria Akkermansia and Blautia, thereby exerting therapeutic effects. This provides theoretical support for treatment strategies based on gut microbiota.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895768 | PMC |
| http://dx.doi.org/10.3389/fmicb.2025.1509548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Altered Bile Acids and Pouch Microbiota Composition in Patients With Chronic Pouchitis.
Inflamm Bowel Dis
March 2025
Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA.
Aging and neurodegeneration: when systemic dysregulations affect brain macrophage heterogeneity.
J Immunol
March 2025
INSERM U1015, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, 94805, France.
Microglia, the major population of brain resident macrophages, differentiate from yolk sac progenitors in the embryo and play multiple nonimmune roles in brain organization throughout development and life. Various microglia subtypes have been described by transcriptomic and proteomic signatures, involved metabolic pathways, morphology, intracellular complexity, time of residency, and ontogeny, both in development and in disease settings. Such macrophage heterogeneity increases with aging or neurodegeneration.
View Article and Find Full Text PDFGut IgA-antibody secreting cells segregate into four Blimp1+ subsets based on differential expression of IgA and Ki-67 and are retained following prolonged αCD20 B cell depletion in mice.
J Immunol
March 2025
Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, United States.
B cell depletion is an efficacious therapy for multiple sclerosis, but its long-term safety profile in the gastrointestinal tract has not been specifically studied. This is of importance because the gut is the largest reservoir of IgA in the body, which maintains gut homeostasis in part by regulating the composition of the gut microbiota. This was addressed by development of a prolonged B cell depletion model using human CD20 transgenic mice and B cell depletion with the anti-human CD20 antibodies rituximab, a humanized mouse monoclonal, and 2H7, the mouse precursor to ocrelizumab.
View Article and Find Full Text PDFDisrupted microbial cross-feeding and altered L-phenylalanine consumption in people living with HIV.
Brief Bioinform
March 2025
Division of Microbiology, Tulane National Primate Research Center, Tulane University, Covington, LA 70433, United States.
This work aims to (1) identify microbial and metabolic alterations and (2) reveal a shift in phenylalanine production-consumption equilibrium in individuals with HIV. We conducted extensive searches in multiple databases [MEDLINE, Web of Science (including Cell Press, Oxford, HighWire, Science Direct, IOS Press, Springer Nature, PNAS, and Wiley), Google Scholar, and Embase] and selected two case-control 16S data sets (GenBank IDs: SRP039076 and EBI ID: ERP003611) for analysis. We assessed alpha and beta diversity, performed univariate tests on genus-level relative abundances, and identified significant microbiome features using random forest.
View Article and Find Full Text PDFNative potential probiotics and postbiotics improve the gut-kidney axis by the modulation of autophagy signaling pathway.
Folia Microbiol (Praha)
March 2025
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
The gut-kidney axis is the bidirectional relationship between the gut microbiota and the kidney function. Chronic inflammatory responses can impair kidney function and probiotics and postbiotics agents can have positive effects on gut health and kidney function by modulating inflammation through affecting autophagy signaling pathway. The aim of the current study was to evaluate the properties of our probiotic and postbiotics to improve kidney health by focusing the autophagy signaling pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!